CTKB vs CUBE · rev $200.5M vs P/E 25, rev $1.07B
Cytek Biosciences Inc (CTKB) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Cytek Biosciences Inc (CTKB) is a medical devices company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported CTKB revenue for 2024-12-31 was $200.5M. Net income was -$6.0M. Revenue was up 3.9% from 2023-12-31 to 2024-12-31. CTKB currently screens at market cap $421.8M.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
CTKB currently screens at market cap $421.8M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the CTKB and CUBE stock pages for the full models.
Not investment advice.